Clinical Trials
48 trialsPembrolizumab in Treating Younger Patients With Recurrent, Progressive, or Refractory High-Grade Gliomas, Diffuse Intrinsic Pontine Gliomas, Hypermutated Brain Tumors, Ependymoma or Medulloblastoma
National Cancer Institute (NCI)
Ex Vivo Drug Sensitivity Testing and Multi-Omics Profiling
Florida International University
Busulfan, Melphalan, Topotecan Hydrochloride, and a Stem Cell Transplant in Treating Patients With Newly Diagnosed or Relapsed Solid Tumor
City of Hope Medical Center
Liposomal Doxorubicin in Treating Children With Refractory Solid Tumors
National Cancer Institute (NCI)
Temozolomide, Vincristine, and Irinotecan in Treating Young Patients With Refractory Solid Tumors
Children's Oncology Group
Ribociclib and Everolimus in Treating Children With Recurrent or Refractory Malignant Brain Tumors
Pediatric Brain Tumor Consortium
Peripheral Stem Cell Transplantation Plus Chemotherapy in Treating Patients With Malignant Solid Tumors
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
MT2004-30: Tomotherapy for Solid Tumors
Masonic Cancer Center, University of Minnesota
Acetylcysteine, Mannitol, Combination Chemotherapy, and Sodium Thiosulfate in Treating Children With Malignant Brain Tumors
OHSU Knight Cancer Institute
Radiolabeled Octreotide in Treating Children With Advanced or Refractory Solid Tumors
University of Iowa
AZD2171 in Treating Young Patients With Recurrent, Progressive, or Refractory Primary CNS Tumors
National Cancer Institute (NCI)
PTC299 in Treating Young Patients With Refractory or Recurrent Primary Central Nervous System Tumors
Pediatric Brain Tumor Consortium
Temozolomide and O6-benzylguanine in Treating Children With Solid Tumors
National Cancer Institute (NCI)
Combination Chemotherapy Plus Gene Therapy in Treating Patients With CNS Tumors
Indiana University
Gamma-Secretase Inhibitor RO4929097 in Treating Young Patients With Relapsed or Refractory Solid Tumors, CNS Tumors, Lymphoma, or T-Cell Leukemia
National Cancer Institute (NCI)
Talotrexin in Treating Young Patients With Recurrent Solid Tumors or Leukemia That is Recurrent or Does Not Respond to Treatment
Children's Oncology Group
Valproic Acid in Treating Young Patients With Recurrent or Refractory Solid Tumors or CNS Tumors
Children's Oncology Group
ABT-888 and Temozolomide in Treating Young Patients With Recurrent or Refractory CNS Tumors
National Cancer Institute (NCI)
Temozolomide and O6-Benzylguanine in Treating Children With Recurrent Brain Tumors
National Cancer Institute (NCI)
Cilengitide in Treating Children With Refractory Primary Brain Tumors
National Cancer Institute (NCI)
Lenalidomide in Treating Young Patients With Recurrent, Progressive, or Refractory CNS Tumors
National Cancer Institute (NCI)
Photodynamic Therapy With Porfimer Sodium in Treating Patients With Refractory Brain Tumors
National Cancer Institute (NCI)
Erlotinib Alone or in Combination With Radiation Therapy in Treating Young Patients With Refractory or Relapsed Malignant Brain Tumors or Newly Diagnosed Brain Stem Glioma
National Cancer Institute (NCI)
Monoclonal Antibody Therapy in Treating Patients With Leptomeningeal Cancer
Memorial Sloan Kettering Cancer Center
Flavopiridol in Treating Children With Relapsed or Refractory Solid Tumors or Lymphomas
National Cancer Institute (NCI)
Vorinostat and Bortezomib in Treating Young Patients With Refractory or Recurrent Solid Tumors, Including Central Nervous System Tumors and Lymphoma
National Cancer Institute (NCI)
High-Dose Methotrexate in Treating Young Patients With Solid Tumors
National Cancer Institute (NCI)
Erlotinib and Temozolomide in Treating Young Patients With Recurrent or Refractory Solid Tumors
National Cancer Institute (NCI)
Oxaliplatin and Irinotecan in Treating Young Patients With Refractory Solid Tumors or Lymphomas
National Cancer Institute (NCI)
Vorinostat and Temozolomide in Treating Young Patients With Relapsed or Refractory Primary Brain Tumors or Spinal Cord Tumors
National Cancer Institute (NCI)
Monoclonal Antibody Therapy in Treating Patients With Recurrent Gliomas
Duke University
O6-benzylguanine and Carmustine in Treating Children With Refractory CNS Tumors
National Cancer Institute (NCI)
FR901228 in Treating Children With Refractory or Recurrent Solid Tumors or Leukemia
National Cancer Institute (NCI)
Ispinesib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Lymphoma
National Cancer Institute (NCI)
DX-8951f in Treating Children With Advanced Solid Tumors or Lymphomas
Daiichi Sankyo
Ixabepilone in Treating Young Patients With Solid Tumors or Leukemia That Haven't Responded to Therapy
National Institutes of Health Clinical Center (CC)
ABT-751 in Treating Young Patients With Refractory Solid Tumors
National Institutes of Health Clinical Center (CC)
Talabostat Combined With Temozolomide or Carboplatin in Treating Young Patients With Relapsed or Refractory Brain Tumors or Other Solid Tumors
National Institutes of Health Clinical Center (CC)
Enzastaurin in Treating Young Patients With Refractory Primary CNS Tumors
Pediatric Brain Tumor Consortium
MK0752 in Treating Young Patients With Recurrent or Refractory CNS Cancer
Pediatric Brain Tumor Consortium
VNP40101M in Treating Young Patients With Recurrent, Progressive, or Refractory Primary Brain Tumors
Pediatric Brain Tumor Consortium
Topotecan in Treating Young Patients With Neoplastic Meningitis Due to Leukemia, Lymphoma, or Solid Tumors
Pediatric Brain Tumor Consortium
Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation or Bone Marrow Transplantation in Treating Patients With Brain Cancer
NYU Langone Health
Chemotherapy and Stem Cell Transplantation in Treating Children With Central Nervous System Cancer
Roswell Park Cancer Institute
Vaccine Therapy and Sargramostim in Treating Patients With Sarcoma or Brain Tumor
Dana-Farber Cancer Institute
SU5416 in Treating Children With Recurrent or Progressive Brain Tumors
Pediatric Brain Tumor Consortium
SCH 66336 in Treating Children With Recurrent or Progressive Brain Tumors
Pediatric Brain Tumor Consortium
Busulfan in Treating Children and Adolescents With Refractory CNS Cancer
Pediatric Brain Tumor Consortium